((自动化翻译由路透提供，请见免责声明 ))
10月24日 - ** 药物开发商 Dyne Therapeutics 股价盘前下跌约 4%，报 31.2 美元
** 摩根大通将其股票评级从 "增持 "下调至 "中性"，将目标价从43美元下调至35美元
** 券商对DYNE-101治疗一种遗传性肌肉疾病的早中期试验的额外结果是否会 "从根本上大幅提高成功的可能性 "或增加近期价值持怀疑态度
** 最近对另一项针对罕见肌肉变性疾病的DYNE-251早中期试验的安全性表示担忧，这可能会使DYN的股价在中期内保持一定的波动范围
** 10家券商中有9家将该股评为 "买入 "或更高评级，1家评为 "持有"；其PT中值为52.5美元--LSEG数据
** 截至上一交易日收盘，该股今年累计涨幅超过一倍，而纳斯达克生物技术指数 的涨幅为7.65%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.